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Simplified citrate anticoagulation for continuous renal replace- sodium citrate is gaining acceptance. However, regional
ment therapy. anticoagulation with citrate increases the complexity of
Background. Regional anticoagulation with trisodium citrate CRRT by requiring customized low-sodium, bicarbonate-is an effective form of anticoagulation for continuous renal re-
free dialysate solutions and/or replacement fluids to mini-placement therapy (CRRT) for patients with contraindications
mize metabolic complications. Moreover, a systemic intra-to heparin. However, because of the metabolic complications
of trisodium citrate, it is a complicated technique requiring venous calcium infusion is required to prevent systemic
specialized dialysis solutions. We have designed a simplified hypocalcemia from the citrate infusion. Unfortunately,
protocol for citrate regional anticoagulation for CRRT.
no commercial dialysate or replacement solutions areMethods. Two percent trisodium citrate was delivered at 250
available, making regional anticoagulation with citratemL/h via the prefilter port of a COBE PRISMA device, with
the rate adjusted to maintain a postfilter ionized calcium (iCa) a labor-intensive therapy for physicians, nursing staff,
0.5 mmol/L. A central calcium gluconate infusion was used to and pharmacy.
maintain a systemic iCa at 1.1 mmol/L. A standard dialysate We initiated a CRRT program at the University of Ala-solution consisting of 0.9% saline, KCl 3 mmol/L, and MgSO4
bama at Birmingham (U.A.B.) two years ago and quickly1 mmol/L was delivered at 1000 mL/h. We retrospectively re-
became aware of the limitations of systemic anticoagula-viewed the outcomes and complications associated with this
protoco1 in 29 patients treated from July 1999 to October 1999, tion with heparin. However, the published trisodium ci-
evaluating the frequency of clotting of the dialyzer, bleeding trate protocols are complex. We sought to develop a
complications, citrate toxicity, and patient mortality.
simple, standard citrate protocol that could be used forResults. The Kaplan–Meier curve for dialyzer survival dem-
most patients requiring CRRT and would minimizeonstrated a 61% survival rate at 48 hours. There were no
episodes of significant bleeding or citrate toxicity. Seventy-two pharmacy time and error. A citrate protocol was insti-
percent of patients died for reasons unrelated to CRRT. tuted for continuous venovenous hemodialysis (CVVHD)
Conclusions. A CRRT protocol using regional 2% trisodium using 2% trisodium citrate as a regional anticoagulantcitrate anticoagulation is not associated with significant bleed-
and normal saline with supplemental potassium and mag-ing complications or citrate toxicity, and represents a simplified
nesium as the dialysate. We report herein our experienceapproach compared with previous applications using 4% tri-
sodium citrate. using this simple protocol.
METHODSContinuous renal replacement therapy (CRRT) is in-
Continuous renal replacement therapy was performedcreasingly used in the United States to treat hemodynam-
ically unstable patients with renal failure. Its major draw- using the COBE PRISMA M60 set with an AN69 dia-
back is the need for anticoagulation. Many intensive care lyzer (effective surface area of 0.6 m2). A double-lumen
unit (ICU) patients cannot tolerate systemic anticoagula- 12F catheter was inserted into either the internal jugular,
tion with heparin, and regional anticoagulation with tri- femoral, or subclavian vein. The blood flow rate was ini-
tially 150 mL/h. The 2% trisodium citrate solution (citrate
70 mmol/L, sodium 210 mmol/L) consisted of 1500 mLKey words: trisodium citrate, acute renal failure, critical care medicine,
dialysis, dialysate, bleeding complications, citrate toxicity. of 5% dextrose and 1500 mL of 4% citrate (4% trisodium
citrate solution; Baxter, McGaw Park, IL, USA). ThisReceived for publication May 22, 2000
was infused prefilter at a rate of 250 mL/h. The infusionand in revised form January 17, 2001
Accepted for publication February 13, 2001 rate was titrated to maintain postfilter ionized calcium
(iCa) of less than 0.5 mmol/L. The standard dialysate, 2001 by the International Society of Nephrology
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Fig. 1. Continuous venovenous hemodialysis
(CVVHD) circuit diagram using 2% trisodium
citrate as the regional anticoagulation. The
2% trisodium citrate is infused prefilter at an
initial rate of 250 mL/h. Calcium gluconate
(93 mEq in 1 L 5% dextrose) is infused system-
ically via a central venous line at initial rate
of 60 mL/h. Dialysate (0.9% saline, KCl 3
mmol/L, MgSO4 1 mmol/L) is delivered at
1000 mL/h.
composed of 0.9% saline with KCl 3 mmol/L and MgSO4 end-stage renal disease (ESRD; Table 1). Baseline labo-
1 mmol/L, was delivered at 1000 mL/h. Ninety-three ratory values are listed in Table 2.
milliequivalents of calcium gluconate in 1 L of 5% dex- We assessed the rates of dialyzer clotting, significant
trose was infused into the patient through a separate episodes of bleeding, citrate toxicity and mortality. Dia-
central venous line at an initial rate of 60 mL/h (Fig. 1). lyzer clotting was defined as clotting of the dialyzer
Dialyzers were routinely changed at 48 hours. within 48 hours of initiating CRRT. Dialyzer survival
Postfilter iCa levels were used to assess the ade- was described using a Kaplan–Meier curve. Censored
quacy of anticoagulation. Postfilter and systemic iCa endpoints included disconnection of the dialyzer for rea-
levels were obtained at the initiation of CRRT, one hour sons unrelated to clotting, bleeding, or citrate toxicity.
after initiation, and then every six hours. The citrate infu- Significant bleeding was defined as the documentation
sion rate was titrated by increments of 10 mL/h to maintain of an acute bleeding episode and/or the need for transfu-
the postfilter iCa between 0.25 and 0.5 mmol/L. The sion of more than two units of packed red blood cells
calcium gluconate infusion was titrated by the ICU nurs- within 48 hours. We detected citrate toxicity by monitor-
ing staff using a standardized protocol to maintain the ing changes in the serum pH, serum sodium, serum bicar-
systemic iCa between 1.0 and 1.1 mmol/L. Serum elec- bonate, and serum iCa levels. Mortality was defined
trolytes, arterial blood gases, and complete blood counts as death at any point during the hospitalization.
were measured frequently and as needed by the nephrol-
ogist and the primary ICU team.
RESULTSThis study retrospectively evaluated the outcomes and
Of the 29 patients, 6 (21%) were disconnected duringcomplications during the first 48 hours of CRRT therapy
the first 48 hours of CRRT for reasons unrelated tousing the 2% trisodium citrate protocol from July 1,
clotting, bleeding, or citrate toxicity. The Kaplan–Meier1999, to October 31, 1999. All adult ICU patients who
survival curve for dialyzer life is shown in Figure 2. Dia-were treated with CRRT using this protocol during this
lyzer survival was 61% at 48 hours. There was no differ-time period were screened for inclusion in the study.
ence in the mean maximum or mean minimum postfilterPatients who died within 48 hours of initiating CRRT
iCa levels between patients who had functional dialyz-(four patients) and patients with incomplete dialysis re-
ers (minimum iCa 0.41  0.08 mmol/L, maximumcords (11 patients) were excluded. Twenty-nine patients
iCa 0.55  0.1 mmol/L) and those whose dialyzerswere included in the final analysis.
clotted (minimum iCa 0.41  0.12 mmol/L, maximumMedical records were used to determine patient char-
iCa 0.53  0.07 mmol/L) within 48 hours of initiatingacteristics and demographics. Of the 29 patients included
CRRT.in the final analysis, 15 were female and 14 were male.
There were no significant bleeding events or episodesThe mean age was 54  16 years, and the mean
of serious citrate toxicity. Five patients (17%) had aAPACHE II score was 23  6 at the time of initiation
systemic iCa 0.9 mmol/L, with a lowest iCa valueof CRRT. Six patients were diabetics. Twenty-three pa-
tients had acute renal failure and six had pre-existing of 0.7 mmol/L. Three of these patients had a low iCa
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Table 1. Patient characteristics
Albumin
Patient Diagnosis Age Sex APACHE IIa ESRD Diabetes g/dL Survived
1 Pre-eclampsia, abruptio placentae 34 F 17 N N Unknown Y
2 Sepsis 57 F 26 Y N 1.4 N
3 Heart transplant with sepsis 44 M 14 N N 2.4 Y
4 AML with sepsis 49 M 16 N N 2.1 N
5 Congestive heart failure 35 M 25 N N 2.3 Y
6 Sepsis s/p bone marrow transplant 41 F 24 N N 1.4 N
7 Hepatorenal syndrome 50 M 23 N N 2.7 N
8 Rhabdomyolysis 32 M 28 N N 2.1 Y
9 Acute renal failure s/p AAA repair 71 M 22 N N 1 N
10 Sepsis 74 F 18 N N 1.4 N
11 Endocarditis 56 F 25 Y Y 2.6 N
12 Toxic epidermal necrolysis 87 F 23 N Y 2.2 N
13 Acetaminophen overdose 28 F 29 N N 2.7 N
14 Hypotension due to arrhythmia 67 F 36 Y Y Unknown N
15 Retroperitoneal bleed s/p PTCA 69 M 27 N N 4.3 N
16 Sepsis s/p bone marrow transplant 36 F 15 N N 2.4 Y
17 Tamponade s/p coronary bypass surgery 60 M 21 Y Y 3.2 N
18 Sepsis from suppurative mediastinitis 70 F 37 N N 1.4 N
19 Ischemic bowel 60 M 22 N N 1.4 N
20 Cirrhosis with pseudomonas sepsis 51 M 21 N N 1.1 N
21 PTLD s/p bone marrow transplant 51 F 30 N N 1.8 N
22 Ischemic bowel 76 F 36 Y N 2.1 N
23 Sepsis s/p bone marrow transplant 52 M 22 N N 1.4 N
24 Motor vehicle accident 60 M 29 N N 0.8 Y
25 Ventricular tachycardia 27 F 14 N N 2.1 N
26 Sepsis with alcohol abuse 72 M 27 N N 1.6 N
27 Thrombotic thrombocytopenic purpura 64 F 18 N N 2.8 Y
28 Sepsis with heart transplant 51 M 14 Y Y 2.7 Y
29 Fournier’s gangrene 56 F 22 N Y 1.6 N
Abbreviations are: AML, acute myelogenous leukemia; AAA, abdominal aortic aneurysm; ESRD, end-stage renal disease; APACHE II, acute physiology and
chronic health evaluation; PTCA, percutaneous transluminal coronary angioplasty; PTLD, post-transplant lymphoproliferative disorder.
a APACHE II score at initiation of continuous renal replacement therapy
prior to citrate infusion. Hypocalcemia was corrected in trauma, or bleeding [1, 2]. Contraindications to systemic
anticoagulation preclude use of CRRT in many patients.two of the five patients using the protocol calcium infu-
sion; the others required additional intravenous calcium. Regional trisodium citrate is an alternative to heparin.
No patient developed symptomatic hypocalcemia. The It provides effective regional anticoagulation by chelat-
highest serum sodium recorded was 150 mEq/L in one ing calcium in the extracorporeal circuit. The anticoagu-
patient. Four patients had an initial serum sodium level lation is reversed by systemic infusion of calcium. The
of less than 130 mEq/L, with a lowest level of 125 mEq/L. metabolism of citrate to CO2 and H2O by the liver, kid-
None of these patients had a rise in the serum sodium neys, and skeletal muscle generates bicarbonate [3]. While
of greater than 9 mEq/L in 24 hours after CRRT with effective, trisodium citrate administration can cause sig-
2% trisodium citrate was initiated. Two patients had a nificant metabolic complications. When used as a 4%
serum pH 7.50, with a maximum recorded pH of 7.53. solution, trisodium citrate is hypertonic (560 mOsm/L)
Only one patient developed a serum bicarbonate 30 and hypernatremic (420 mmol/L) and can result in hyper-
mEq/L (33 mEq/L). Twenty-one patients (72%) died natremia and metabolic alkalosis. Hypocalcemia can re-
during their hospitalization; these deaths were related sult from chelation of calcium by citrate. Systemic iCa
to the patients’ underlying disease processes and not levels below 0.8 mmol/L can cause potentially fatal ar-
CRRT complications. rhythmias [4], and the use of concentrated trisodium
citrate solutions has been proscribed by the Food and
Drug Administration [5].
DISCUSSION Several protocols using trisodium citrate have been
described (Table 3). A direct comparison of the efficacyRecent advances in CRRT have led to an increase in
its use for treating acute renal failure in critically ill and complications of the four protocols is difficult, as
they have not been evaluated in a randomized clinicalpatients. Systemic anticoagulation with heparin is associ-
ated with a high incidence of hemorrhagic complications trial. Furthermore, they vary not only in the amount of
citrate delivered, but also in the type of CRRT modality,in these patients, many of whom have had recent surgery,
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Table 2. Patient baseline labs
Total Ca iCa
Patient mg/dL mmol/L pH Hct Platelet PT/INR PTT
1 7.1 1.03 7.35 28 140 16.1/1.2 38
2 12 1.3 7.42 25 112 18.9/1.6 47
3 7.4 0.86 7.43 32 229 22.1/1.8 32
4 8 1.14 7.47 23 180 16.1/1.3 44
5 N/A 1.05 7.36 26 247 17.2/1.4 29
6 7.7 1.09 7.41 34 14 17.1/1.4 41
7 7.8 0.98 7.45 34 79 21.4/1.8 38
8 6.9 0.77 7.36 44 346 28.1/2.6 200
9 5.2 1 7.33 30 100 81.6/10.3 128
10 9.3 1.21 7.35 34 114 22.3/1.8 40
11 7.9 1.14 7.32 20 61 17.6/1.3 27
12 6.7 0.98 N/A 33 119 24.2/2.0 36
13 6 0.82 7.38 29 90 50/5.2 62
14 9.4 1.1 7.09 35 201 81/9.6 61
15 N/A 1.07 N/A 32 44 14.6/1.1 29 Fig. 2. Kaplan–Meier curve for dialyzer survival.
16 8.8 1.25 7.29 29 67 N/A 199
17 N/A 1.17 7.36 29 265 14.7/1.1 35
18 8.2 1.24 7.21 29 38 30.7/2.8 48
19 N/A 1.21 7.34 29 75 19.2/1.5 30
20 8.1 1.1 7.3 26 115 20.5/1.6 89
21 8.1 1.01 7.21 16 156 28.7/2.5 200 to normal in all five patients by administration of intrave-
22 8.7 1.03 7.14 31 42 24.7/2.1 46
nous calcium. This underscores the importance of close23 9.3 1.2 7.4 27 52 17.5/1.3 24
24 7.8 1.24 N/A 26 166 15.5/1.1 39 monitoring of iCa levels, particularly in critically ill
25 6.5 0.93 N/A 23 118 23.4/1.9 31 patients with initial ionized hypocalcemia. These pa-
26 N/A 0.91 7.3 29 360 N/A N/A
tients, especially those who cannot metabolize citrate,27 6.9 N/A 7.55 28 28 14.9/1.1 37
28 10.3 1.39 N/A 28 171 N/A N/A may require even more aggressive calcium monitoring
29 7.2 1.14 7.32 25 213 20.8/1.7 77 and repletion than described by the present protocol.
Abbreviations are: Hct, hematocrit; PT, prothrombin time; INR, international Trisodium citrate should be used cautiously in patients
normalized ratio; PTT, partial thromboplastin time; N/A, not available; Ca,
with liver impairment. Ineffective citrate removal by im-calcium; iCa, ionized calcium.
paired hepatic metabolism can result in systemic hyper-
calcemia, hypercitric acidemia, and ionized hypocalcemia,
despite large amounts of calcium [8]. These patients may
require a reduced infusion rate of citrate than providedthe blood flow rate, and the assessment of adequate
by this protocol. Because of the increased risk, totalanticoagulation. These factors may affect dialyzer pat-
calcium levels should be measured daily in these patientsency and clotting. However, Kaplan–Meier curves in two
to detect an increased ionized to total calcium ratio,studies [1, 6] can be used to compare dialyzer survival
indicating citrate toxicity. In addition, rapid turnaroundat 48 hours. A comparison of these curves reveals an
of serum citrate measurements should become availableapproximate 48-hour survival rate of 50% in the study
at tertiary care centers that utilize regional citrate antico-by Mehta et al [1] and 70% in the study by Kutsogiannis
agulation for CRRT.et al [6], compared with 61% with the 2% trisodium
There were no significant complications due to hyper-citrate protocol in this study.
natremia or the rate of change in serum sodium concen-Asymptomatic hypocalcemia occurred with all four
tration, despite using a normal saline bath. The maximumprotocols [1, 6, 7]. In Mehta et al’s study, recorded sys-
serum sodium level was 150 mEq/L. Hypernatremia wastemic iCa levels were between 0.61 and 1.44 mmol/L
treated by increasing free water administration to the[1]. While no episodes of symptomatic hypocalcemia or
patient. It is important to consider the contribution ofbleeding were reported, three episodes of metabolic alka-
concomitant fluids administered to the serum sodium levellosis occurred [1]. Palsson and Niles observed two patients
in the management of these patients. We recommendwith asymptomatic hypocalcemia (lowest iCa level of
obtaining serum electrolytes at least every eight hours in0.7 mmol/L) and reported no bleeding episodes [7]. Kut-
patients undergoing CRRT with citrate anticoagulation.sogiannis et al reported three episodes of metabolic alka-
There were no bleeding complications observed dur-losis, no symptomatic episodes of hypocalemia, and a
ing this study. However, we only assessed complicationsdefinite bleeding rate of 0.045 events per person-day [6].
during the first 48 hours of therapy, and this makes itThe major metabolic complication of the 2% citrate
difficult to compare the bleeding rate of the 2% citrateprotocol was asymptomatic hypocalcemia, although none
protocol to other citrate protocols. A more importantof the five affected patients had clinically significant ar-
rhythmias. Systemic ionized calcium levels were corrected comparison of bleeding complications would be between
Tolwani et al: Simplified citrate in CRRT374
Table 3. Comparison of citrate protocols
N Modality Blood flow rate Citrate delivery Dialysate Replacement fluid Patency at 48 hours
Mehta et al [1] 11 CAVHD 52–125 mL/min 23.8 mmol/ha Na 117 mEq/L
Cl 122.5 mEq/L 50%
K 4 mEq/L 0.9% Saline
Mg 1.5 mEq/L
Dextrose 2.5%
Palsson et al. [7] 17 CVVH 180 mL/min 18.6 mmol/hb Na 140 mEq/L




Kutsogiannis et al. [6] 9 CVVHDF 125 mL/min 25 mmol/ha Na 110 mEq/L Na 110 mEq/L 70%
Cl 110 mEq/L Cl 110 mEq/L
Mg 1.5 mEq/L Mg 1.5 mEq/L
Varied NaHCO3
Tolwani et al. (current study) 23 CVVHD 125–150 mL/min 17.5 mmol/ha 0.9% Saline
K 3 mEq/L N/A 61%
Mg 2 mEq/L
Abbreviations are: CAVHD, continuous arteriovenous hemodialysis; CVVH, continuous venovenous hemofiltration; CVVHDF, continuous venovenous hemodiafil-
tration; CVVHD, continuous venovenous hemodialysis; N/A, not available.
a Initial citrate infusion rate
b Average citrate infusion rate
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